The reproducible and statistically significant difference in the number of SPTAN1 seropositive patients in both the initial and validation cohorts provides strong evidence for the potential utility of anti-SPTAN1 IgG as a diagnostic marker for MS. This evidence concerns the gene SPTAN1 and myeloid sarcoma.